Cargando…

AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals

BACKGROUND: The Measurement Tool to Assess systematic Reviews (AMSTAR) 2 is a critical appraisal tool for systematic reviews (SRs) and meta-analyses (MAs) of interventions. We aimed to perform the first AMSTAR 2-based quality assessment of heart failure-related studies. METHODS: Eleven high-impact j...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lin, Asemota, Iriagbonse, Liu, Bolun, Gomez-Valencia, Javier, Lin, Lifeng, Arif, Abdul Wahab, Siddiqi, Tariq Jamal, Usman, Muhammad Shariq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308914/
https://www.ncbi.nlm.nih.gov/pubmed/35871099
http://dx.doi.org/10.1186/s13643-022-02029-9
_version_ 1784753044994392064
author Li, Lin
Asemota, Iriagbonse
Liu, Bolun
Gomez-Valencia, Javier
Lin, Lifeng
Arif, Abdul Wahab
Siddiqi, Tariq Jamal
Usman, Muhammad Shariq
author_facet Li, Lin
Asemota, Iriagbonse
Liu, Bolun
Gomez-Valencia, Javier
Lin, Lifeng
Arif, Abdul Wahab
Siddiqi, Tariq Jamal
Usman, Muhammad Shariq
author_sort Li, Lin
collection PubMed
description BACKGROUND: The Measurement Tool to Assess systematic Reviews (AMSTAR) 2 is a critical appraisal tool for systematic reviews (SRs) and meta-analyses (MAs) of interventions. We aimed to perform the first AMSTAR 2-based quality assessment of heart failure-related studies. METHODS: Eleven high-impact journals were searched from 2009 to 2019. The included studies were assessed on the basis of 16 domains. Seven domains were deemed critical for high-quality studies. On the basis of the performance in these 16 domains with different weights, overall ratings were generated, and the quality was determined to be “high,” “moderate,” “low,” or “critically low.” RESULTS: Eighty-one heart failure-related SRs with MAs were included. Overall, 79 studies were of “critically low quality” and two were of “low quality.” These findings were attributed to insufficiency in the following critical domains: a priori protocols (compliance rate, 5%), complete list of exclusions with justification (5%), risk of bias assessment (69%), meta-analysis methodology (78%), and investigation of publication bias (60%). CONCLUSIONS: The low ratings for these potential high-quality heart failure-related SRs and MAs challenge the discrimination capacity of AMSTAR 2. In addition to identifying certain areas of insufficiency, these findings indicate the need to justify or modify AMSTAR 2’s rating rules. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13643-022-02029-9.
format Online
Article
Text
id pubmed-9308914
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93089142022-07-25 AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals Li, Lin Asemota, Iriagbonse Liu, Bolun Gomez-Valencia, Javier Lin, Lifeng Arif, Abdul Wahab Siddiqi, Tariq Jamal Usman, Muhammad Shariq Syst Rev Research BACKGROUND: The Measurement Tool to Assess systematic Reviews (AMSTAR) 2 is a critical appraisal tool for systematic reviews (SRs) and meta-analyses (MAs) of interventions. We aimed to perform the first AMSTAR 2-based quality assessment of heart failure-related studies. METHODS: Eleven high-impact journals were searched from 2009 to 2019. The included studies were assessed on the basis of 16 domains. Seven domains were deemed critical for high-quality studies. On the basis of the performance in these 16 domains with different weights, overall ratings were generated, and the quality was determined to be “high,” “moderate,” “low,” or “critically low.” RESULTS: Eighty-one heart failure-related SRs with MAs were included. Overall, 79 studies were of “critically low quality” and two were of “low quality.” These findings were attributed to insufficiency in the following critical domains: a priori protocols (compliance rate, 5%), complete list of exclusions with justification (5%), risk of bias assessment (69%), meta-analysis methodology (78%), and investigation of publication bias (60%). CONCLUSIONS: The low ratings for these potential high-quality heart failure-related SRs and MAs challenge the discrimination capacity of AMSTAR 2. In addition to identifying certain areas of insufficiency, these findings indicate the need to justify or modify AMSTAR 2’s rating rules. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13643-022-02029-9. BioMed Central 2022-07-23 /pmc/articles/PMC9308914/ /pubmed/35871099 http://dx.doi.org/10.1186/s13643-022-02029-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Lin
Asemota, Iriagbonse
Liu, Bolun
Gomez-Valencia, Javier
Lin, Lifeng
Arif, Abdul Wahab
Siddiqi, Tariq Jamal
Usman, Muhammad Shariq
AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals
title AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals
title_full AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals
title_fullStr AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals
title_full_unstemmed AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals
title_short AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals
title_sort amstar 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308914/
https://www.ncbi.nlm.nih.gov/pubmed/35871099
http://dx.doi.org/10.1186/s13643-022-02029-9
work_keys_str_mv AT lilin amstar2appraisalofsystematicreviewsandmetaanalysesinthefieldofheartfailurefromhighimpactjournals
AT asemotairiagbonse amstar2appraisalofsystematicreviewsandmetaanalysesinthefieldofheartfailurefromhighimpactjournals
AT liubolun amstar2appraisalofsystematicreviewsandmetaanalysesinthefieldofheartfailurefromhighimpactjournals
AT gomezvalenciajavier amstar2appraisalofsystematicreviewsandmetaanalysesinthefieldofheartfailurefromhighimpactjournals
AT linlifeng amstar2appraisalofsystematicreviewsandmetaanalysesinthefieldofheartfailurefromhighimpactjournals
AT arifabdulwahab amstar2appraisalofsystematicreviewsandmetaanalysesinthefieldofheartfailurefromhighimpactjournals
AT siddiqitariqjamal amstar2appraisalofsystematicreviewsandmetaanalysesinthefieldofheartfailurefromhighimpactjournals
AT usmanmuhammadshariq amstar2appraisalofsystematicreviewsandmetaanalysesinthefieldofheartfailurefromhighimpactjournals